Connor, Clark & Lunn Investment Management Ltd. Janux Therapeutics, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$22 Billion
Q2 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2024 May 09, 2024	SELL	$7.93 - $49.75 $46,977 - $294,719	-5,924 Reduced 46.22%	6,892 $259,000
Q4 2023 Feb 09, 2024	BUY	$5.85 - $11.7 $74,973 - $149,947	12,816 New	12,816 $137,000

Others Institutions Holding JANX

# of Institutions

160

Shares Held

37.2M

Call Options Held

70.4K

Put Options Held

101K

Ra Capital Management, L.P. Boston, MA

9.17M
Shares

$499 Million
5.79% of portfolio
Orbimed Advisors LLC San Diego, CA

2.98M
Shares

$162 Million
3.01% of portfolio
Black Rock Inc. New York, NY

2.34M
Shares

$127 Million
0.0% of portfolio
Adage Capital Partners Gp, L.L.C. Boston, MA

2.33M
Shares

$127 Million
0.19% of portfolio
Janus Henderson Group PLC London, X0

1.8M
Shares

$98 Million
0.04% of portfolio

View Full List

About Janux Therapeutics, Inc.

Ticker JANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,663,000
Market Cap $2.27B
Description
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...

More about JANX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account